Weekly Analysts’ Ratings Changes for Mazor Robotics (MZOR)

A number of firms have modified their ratings and price targets on shares of Mazor Robotics (NASDAQ: MZOR) recently:

  • 2/8/2018 – Mazor Robotics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
  • 2/2/2018 – Mazor Robotics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 2/2/2018 – Mazor Robotics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $74.00 price target on the stock. According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
  • 2/1/2018 – Mazor Robotics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
  • 1/24/2018 – Mazor Robotics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $70.00 price target on the stock. According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
  • 1/23/2018 – Mazor Robotics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/13/2018 – Mazor Robotics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
  • 1/13/2018 – Mazor Robotics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/9/2018 – Mazor Robotics had its “sell” rating reaffirmed by analysts at Barclays PLC. They now have a $36.00 price target on the stock.

Mazor Robotics Ltd – (MZOR) traded down $2.09 during trading hours on Wednesday, reaching $59.21. 447,300 shares of the company’s stock were exchanged, compared to its average volume of 570,013. The stock has a market cap of $1,590.00, a PE ratio of -84.59 and a beta of 1.16. Mazor Robotics Ltd – has a one year low of $21.55 and a one year high of $69.37.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Receive News & Ratings for Mazor Robotics Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply